Higher volumes may have benefited sales of Blincyto, Nplate, Repatha, Otezla and Aimovig. Please note that Otezla was purchased by Amgen from Celgene in November 2019 as the latter had to divest the drug in order to complete its merger with Bristol-Myers ( BMY - Free Report ). The Zacks Consensus Estimate for Otezla is $583 million.